FLUORESCENCE BASED DETECTION AND DIAGNOSIS OF MALIGNANCY

基于荧光的恶性肿瘤检测和诊断

基本信息

  • 批准号:
    6188984
  • 负责人:
  • 金额:
    $ 12.27万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2000
  • 资助国家:
    美国
  • 起止时间:
    2000-05-01 至 2002-04-30
  • 项目状态:
    已结题

项目摘要

Long-term goal of the proposed research is to establish a non-invasive real-time clinical capability for early detection, diagnosis, monitoring and screening of pre-malignant and malignant lesions. Based on laser-induced fluorescence (LIF) techniques for characterization of 5-aminolevulinic acid (ALA)- induced protoporphyrin IX (PpIX) fluorescence and of endogenous fluorescence, the proposed approach is unique in combining emissions from these 2 types of fluorescence into one maximally informative diagnostic measurement event by utilizing the same excitation wavelength (405nm). Use of topical ALA will minimize procedure duration, side-effects and ensure patient acceptance of this technique. Although this clinical proposal focuses on intra-oral dysplasia and carcinoma, results will translate directly to many other areas of the body. The information gained is also applicable to photodynamic therapeutic modalities. Specific aims: To (l) characterize ALA-induced and endogenous fluorescence in healthy human oral mucosa, dysplasia and squamous cell carcinoma, (2) determine time-based pharmacokinetics of ALA conversion to PpIX in healthy, dysplastic and malignant oral tissue (3) establish a basis for translation of photodynamic data from the hamster model to humans (4) identify effects of co-existing oral pathologies on LIF, (5) evaluate LIF-based differentiation between conditions with a leukoplakic clinical presentation (6) compare diagnostic capability of LIF with conventional measures. Human healthy, premalignant and malignant oral mucosa will be analyzed using low-light level fluorescence cryomicroscopy in biopsies from 60 patients. ALA will be applied as a cream or mouthrinse for 15-90 mins. prior to biopsy. Excitation will occur at 405nm, PpIX detection at 635nm, autofluorescence detection at 470nm. The optimum interval between ALA application and PpIX fluorescence measurement to maximize tumor:healthy tissue fluorescence ratio will be identified. Fluorescence characteristics will be compared with histological status. Fluorescence characteristics of conditions co-existing with dysplasia, carcinoma and of pathologies clinically resembling leukoplakia, carcinoma will be identified. Selectivity, specificity and predictive capability of LIF will be established. This work will provide the basis for non-invasive, real-time, in vivo identification of the need for biopsies, thus minimizing surgical sampling, and permitting early treatment. Fast, non-specialist screening of at risk populations will become possible.
拟议研究的长期目标是建立一种非侵入性的实时临床能力,用于早期检测、诊断、监测和筛查癌前病变和恶性病变。基于激光诱导荧光(LIF)技术表征5-氨基乙酰丙酸(ALA)诱导的原卟啉IX(PpIX)荧光和内源性荧光,所提出的方法是独特的,通过利用相同的激发波长(405 nm)将来自这2种类型的荧光的发射组合成一个最大信息量的诊断测量事件。使用局部ALA将最大限度地减少手术时间,副作用,并确保患者接受这种技术。虽然这项临床建议的重点是口腔内发育不良和癌症,结果将直接转化为身体的许多其他领域。所获得的信息也适用于光动力治疗方式。具体目标:为了(1)表征健康人口腔粘膜、异型增生和鳞状细胞癌中ALA诱导的和内源性荧光,(2)确定健康、异型增生和恶性口腔组织中ALA转化为PpIX的基于时间的药代动力学,(3)建立将来自仓鼠模型的光动力学数据转化为人的基础,(4)鉴定共存口腔病理对LIF的影响,(5)评估具有白斑临床表现的病症之间基于LIF的区分(6)比较LIF与常规测量的诊断能力。人类健康,癌前和恶性口腔粘膜将进行分析,使用低光水平荧光冷冻显微镜活检60例患者。ALA将作为乳霜或漱口水使用15-90分钟。在活检之前。激发将在405 nm处发生,PpIX检测在635 nm处发生,自发荧光检测在470 nm处发生。将确定ALA应用和PpIX荧光测量之间的最佳间隔,以使肿瘤:健康组织荧光比率最大化。将荧光特征与组织学状态进行比较。将识别与异型增生、癌共存的病症以及临床上类似白斑、癌的病理的荧光特征。将确定LIF的选择性、特异性和预测能力。这项工作将为非侵入性、实时、体内识别活检的需要提供基础,从而最大限度地减少手术取样,并允许早期治疗。对高危人群进行快速、非专家筛查将成为可能。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

PETRA E WILDER-SMITH其他文献

PETRA E WILDER-SMITH的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('PETRA E WILDER-SMITH', 18)}}的其他基金

High-resolution reflective microscope
高分辨率反射显微镜
  • 批准号:
    10546300
  • 财政年份:
    2022
  • 资助金额:
    $ 12.27万
  • 项目类别:
Mobile oral cancer screening system for low-resource settings
适用于资源匮乏环境的移动口腔癌筛查系统
  • 批准号:
    10323692
  • 财政年份:
    2021
  • 资助金额:
    $ 12.27万
  • 项目类别:
A Low-Cost Simple Oral Cancer Screening Device for Low-Resource Settings
适用于资源匮乏环境的低成本简单口腔癌筛查设备
  • 批准号:
    8267452
  • 财政年份:
    2012
  • 资助金额:
    $ 12.27万
  • 项目类别:
A Low-Cost Simple Oral Cancer Screening Device for Low-Resource Settings
适用于资源匮乏环境的低成本简单口腔癌筛查设备
  • 批准号:
    8475596
  • 财政年份:
    2012
  • 资助金额:
    $ 12.27万
  • 项目类别:
REVERSAL OF MUCOSITIS BY GMSC-BASED THERAPY
基于 GMSC 的疗法逆转粘膜炎
  • 批准号:
    8362697
  • 财政年份:
    2011
  • 资助金额:
    $ 12.27万
  • 项目类别:
CHARACTERIZATION OF BLOOD FLOW IN DENTAL PULP
牙髓中血流的表征
  • 批准号:
    8362688
  • 财政年份:
    2011
  • 资助金额:
    $ 12.27万
  • 项目类别:
REVERSAL OF MUCOSITIS BY GMSC-BASED THERAPY
基于 GMSC 的疗法逆转粘膜炎
  • 批准号:
    8362715
  • 财政年份:
    2011
  • 资助金额:
    $ 12.27万
  • 项目类别:
REVERSAL OF MUCOSITIS BY GMSC-BASED THERAPY
基于 GMSC 的疗法逆转粘膜炎
  • 批准号:
    8169526
  • 财政年份:
    2010
  • 资助金额:
    $ 12.27万
  • 项目类别:
CHARACTERIZATION OF BLOOD FLOW IN DENTAL PULP
牙髓中血流的表征
  • 批准号:
    8169517
  • 财政年份:
    2010
  • 资助金额:
    $ 12.27万
  • 项目类别:
FLUORESCENCE BASED DETECTION AND DIAGNOSIS OF MALIGNANCY
基于荧光的恶性肿瘤检测和诊断
  • 批准号:
    6378039
  • 财政年份:
    2000
  • 资助金额:
    $ 12.27万
  • 项目类别:

相似海外基金

Candida and Candidiasis Conference 2023
2023 年念珠菌和念珠菌病会议
  • 批准号:
    10682982
  • 财政年份:
    2023
  • 资助金额:
    $ 12.27万
  • 项目类别:
Functional analysis of the signaling adaptor protein during oral candidiasis
口腔念珠菌病期间信号转接蛋白的功能分析
  • 批准号:
    23H03076
  • 财政年份:
    2023
  • 资助金额:
    $ 12.27万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Discovery of bacterial consortia to treat recurrent vulvovaginal candidiasis: a generalizable platform for phenotypic microbial community screening
发现治疗复发性外阴阴道念珠菌病的细菌群落:表型微生物群落筛查的通用平台
  • 批准号:
    10383360
  • 财政年份:
    2022
  • 资助金额:
    $ 12.27万
  • 项目类别:
Development of theranostics system for oral candidiasis
口腔念珠菌病治疗诊断系统的开发
  • 批准号:
    22K10128
  • 财政年份:
    2022
  • 资助金额:
    $ 12.27万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
The development of invasive candidiasis prevention based on interactions between gastrointestinal microbiota and Candida species
基于胃肠道微生物群和念珠菌物种之间相互作用的侵袭性念珠菌病预防的发展
  • 批准号:
    20K17477
  • 财政年份:
    2022
  • 资助金额:
    $ 12.27万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Host and Fungal Regulation of Type 17 Immunity to Oral Candidiasis
17 型口腔念珠菌病免疫的宿主和真菌调节
  • 批准号:
    10551422
  • 财政年份:
    2022
  • 资助金额:
    $ 12.27万
  • 项目类别:
Host and Fungal Regulation of Type 17 Immunity to Oral Candidiasis
17 型口腔念珠菌病免疫的宿主和真菌调控
  • 批准号:
    10673918
  • 财政年份:
    2022
  • 资助金额:
    $ 12.27万
  • 项目类别:
Mechanisms of renal protection against disseminated candidiasis
抵抗播散性念珠菌病的肾脏保护机制
  • 批准号:
    10376250
  • 财政年份:
    2021
  • 资助金额:
    $ 12.27万
  • 项目类别:
Role of environmental iron in Candida albicans cell wall remodeling and its effect on host-pathogen interaction during oropharyngeal candidiasis
环境铁在口咽念珠菌病期间白色念珠菌细胞壁重塑中的作用及其对宿主-病原体相互作用的影响
  • 批准号:
    10647656
  • 财政年份:
    2021
  • 资助金额:
    $ 12.27万
  • 项目类别:
(Mis)Managing Microbiomes: Experiences and Challenges with Chronic Vulvovaginal Candidiasis in Primary Health Care
(错误)管理微生物组:初级卫生保健中慢性外阴阴道念珠菌病的经验和挑战
  • 批准号:
    457221
  • 财政年份:
    2021
  • 资助金额:
    $ 12.27万
  • 项目类别:
    Studentship Programs
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了